Status:
UNKNOWN
NK Cell Deregulation in HBV Patients
Lead Sponsor:
University Hospital, Limoges
Conditions:
Hepatitis B Virus
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Natural Killer (NK) cells play a large role in the innate immune response as they are equipped to kill infected or tumor cells. They express a panel of activating and inhibitory receptors that regulat...
Detailed Description
Using a previous cohort from the Limoges Hospital, the investigators have identified by multi-parametric flow cytometry phenotypic, cytokine and signaling molecules that are altered in NK cells from C...
Eligibility Criteria
Inclusion
- Patients must meet all of the following inclusion criteria to be eligible for participation in this study:
- Male or female, age ≥18 years
- HBV infection or chronic HBV infection
- Willing and able to provide written informed consent
- Healthy donors must meet all of the following inclusion criteria to be eligible for participation in this study:
- Male or female, age between 18 and 50 years
- Willing and able to provide written informed consent
Exclusion
- Subjects who meet any of the following exclusion criteria are not to be enrolled in this study:
- Infection with hepatitis C virus (HCV) or human immunodeficiency virus (HIV)
- Chronic liver disease of a non-HBV etiology
- Immune or cancerous disease
Key Trial Info
Start Date :
December 11 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2024
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT03761875
Start Date
December 11 2018
End Date
March 1 2024
Last Update
May 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Limoges Hospital
Limoges, France, 87 042